Our results indicated that PRADX activates NF-κB pathway by suppressing UBXN1 expression in both GBM and COAD cells, indicating that a single lncRNA may be used as a marker or therapeutic target against multiple tumors. This evidence concerns the gene NFKB1 and glioblastoma.